Predictive impact of various molecular forms of PSA-related indices on developing prostate cancer and tumor aggressiveness

• Project/Area Number: 15K10575
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Gunma University
• Principal Investigator: Ito Kazuto 群馬大学, 大学院医学系研究科, 准教授 (00302472)
• Research Collaborator: SUZUKI Rie 群馬大学, 医学部附属病院 泌尿器科, 助手
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 前立腺癌 / 前立腺特異抗原 / 遊離型PSA / proPSA / PSA

Outline of Final Research Achievements

The baseline free to total prostate-specific antigen ratio was a significant
predictor of prostate cancer development. The odds ratio was 6.08 in the lowest quintile baseline free to total prostate-specific antigen ratio subgroup. No serum indices at diagnosis were associated with tumor aggressiveness. The Prostate Health Index velocity and [-2]proenzyme prostate-specific antigen/free prostate-specific antigen velocity significantly increased in patients with higher risk D’Amico risk groups and higher Gleason scores.
Those indices could be useful for a more effective individualized screening system. Longitudinal changes in [-2] proenzyme prostate-specific antigen-related indices seem to correlate with tumor aggressiveness, and they could be used as prognostic tool before treatment and during active surveillance.

Research Products

• [Journal Article] Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL. (2017)
  • Author(s): Fujizuka Y, Ito K, Oki R, Suzuki R, Sekine Y, Koike H, Matsui H, Shibata Y, Suzuki K.
  • Journal Title: Int J Urol Volume: 24 Issue: 8 Pages: 602-609
  • DOI: 10.1111/iju.13381
  • Peer Reviewed
• [Journal Article] Predictive impact of various molecular forms of PSA-related indices on developing prostate cancer and tumor aggressiveness in men with baseline PSA <2.0 ng/ml (2017)
  • Author(s): Yuji Fujizuka, Kazuto Ito, Ryo Oki, Rie Suzuki, Yoshitaka Sekine, Hidekazu Koike, Hiroshi Matsui, Yasuhiro Shibata, Kazuhiro Suzuki
  • Journal Title: International Journal of Urology Volume: 印刷中
  • Peer Reviewed
• [Journal Article] Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countries (2015)
  • Author(s): Okihara K, Ochiai A, Kamoi K, Fujizuka Y, Miki T, Ito K.
  • Journal Title: Int J Urol. 22: 334-41. Volume: 22 Issue: 4 Pages: 334-341
  • DOI: 10.1111/iju.12701
  • Peer Reviewed
• [Journal Article] 新しい腫瘍マーカーの臨床応用可能性と展望：proPSA の最新研究成果と本邦での臨床性能試験進捗状況 (2015)
  • Author(s): 伊藤一人
  • Journal Title: 泌尿器外科 Volume: 28 Pages: 1461-1463
• [Presentation] 新規バイオマーカー[-2]proPSA：前立腺癌診療における臨床応用の可能性 (2016)
  • Author(s): 伊藤一人
  • Organizer: 第32回前立腺シンポジウム
  • Place of Presentation: 東京
  • Year and Date: 2016-12-11
  • Invited
• [Presentation] 前立腺癌診療におけるproPSAの臨床応用の可能性 (2016)
  • Author(s): 伊藤一人
  • Organizer: 第８１回日本泌尿器科学会東部総会
  • Place of Presentation: 青森
  • Year and Date: 2016-10-08
  • Invited
• [Presentation] 新規バイオマーカー[-2]proPSA：前立腺癌診療における臨床応用の可能性を探る (2016)
  • Author(s): 伊藤一人
  • Organizer: 第63回日本臨床検査医学会・第65回日本医学検査学会合同学会
  • Place of Presentation: 神戸
  • Year and Date: 2016-09-02
  • Invited